ACRS Aclaris Therapeutics, Inc.
USHealthcareAs of 2026-07-10 16:00
Why ACRS matters now
Aclaris Therapeutics, Inc. (ACRS) is a US stock in Healthcare. The latest InvestLog snapshot shows $5.58 with -2.28% on the session and $672.9M in market capitalization; recent performance reads 1-month +1.12% and YTD +49.50%.
The latest financial table shown here is Q1 2026, with revenue of $2.0M, net income of $-19.8M, and EPS of $-0.15. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -9.6%.
The latest indexable market news headline is "Strength Seen in Aclaris (ACRS): Can Its 5.4% Jump Turn into More Strength?" from Zacks Investment Research.
Additional event context on this page matters because analyst consensus is Buy with a median target of $10.00; recent insider activity includes GOWEN MAXINE filing M-Exempt. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
4.04
P/S
64.86
EV/EBITDA
-7.31
DCF Value
$-0.92
FCF Yield
-9.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
76.3%
Operating Margin
-961.9%
Net Margin
-832.6%
ROE
-55.9%
ROA
-35.1%
ROIC
-46.8%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $2.0M | $-19.8M | $-0.15 |
| Q4 2025 | $1.3M | $-19.8M | $-0.16 |
| FY 2025 | $7.8M | $-64.9M | $-0.53 |
| Q3 2025 | $3.3M | $-14.6M | $-0.12 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$10.60
Target (Median)
$10.00
Target Range
$10.00 - $12.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.80
Aclaris Therapeutics, Inc., a biopharmaceutical firm operating in the United States, is currently in the clinical development phase, focused on creating novel therapeutic agents for various immune-inflammatory conditions. The company's operations are divided into two primary divisions: the Therapeutics segment, dedicated to discovering and progressing innovative treatments to address crucial unmet needs in immuno-inflammatory disorders; and the Contract Research segment, which delivers specialized laboratory services. The company's pipeline features several investigational compounds. Among these is Zunsemetinib, an MK2 inhibitor, being developed to treat moderate to severe cases of rheumatoid arthritis, psoriatic arthritis, and hidradenitis suppurativa. Another significant candidate is ATI-1777, a soft JAK 1/3 inhibitor, intended for the management of moderate to severe atopic dermatitis. Additionally, Aclaris is advancing ATI-2138, an ITK/TXK/JAK3 inhibitor, as a potential intervention for T cell-mediated autoimmune diseases; a Gut-Biased Program targeting inflammatory bowel disease; and ATI-2231, an MK2 inhibitor, for the treatment of pancreatic and metastatic breast cancer. Established in 2012, Aclaris Therapeutics, Inc. has its corporate headquarters situated in Wayne, Pennsylvania.